Bellerophon Announces Closing of $7 Million Public Offering of Common Stock
January 25, 2019 16:05 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Jan. 25, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the closing...
Bellerophon Announces Pricing of $7 Million Public Offering of Common Stock
January 23, 2019 06:00 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Jan. 23, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the pricing...
Bellerophon Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
January 22, 2019 16:44 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it...
Bellerophon Announces Top-line Results from Cohort 1 of the INOpulse® Phase 2b Clinical Trial for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
January 07, 2019 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced top-line...
Bellerophon Provides Business Update and Reports Third Quarter 2018 Financial Results
November 07, 2018 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business...
Bellerophon Provides Update on INOpulse® Phase 2b Clinical Program for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
October 09, 2018 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided an update on...
Bellerophon Therapeutics to Present at Rodman & Renshaw 20th Annual Global Investment Conference
August 29, 2018 08:00 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that Fabian...
Bellerophon Announces Results of Interim Analysis of Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension
August 07, 2018 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that the Data...
Bellerophon Provides Business Update and Reports Second Quarter 2018 Financial Results
August 01, 2018 08:40 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business...
Bellerophon Therapeutics to Participate on Panel at JMP Securities Life Sciences Conference
June 12, 2018 08:00 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., June 12, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it will...